See a very important announcement from
ALD Connect plans to submit a Letter of Interest to the FDA to host an Externally-Led Patient-Focused Drug Development meeting in April 2022. The primary goal of patient-focused drug development is to better incorporate the patient’s voice in drug development and evaluation.
Our target population will be adults with ALD (men with AMN, men with cerebral ALD, and women with ALD). We are working hard on our proposal and are curious to know how many community members would be interested in participating.
Our committee believes it would send a powerful message for FDA representatives to see patients in person – to witness the challenges with activities of daily living and quality of life – but we also recognize that some patients and caregivers are not able travel.
The above link will take you to the original Instagram post. If you cannot make that work, let me know and I will send you over an email that includes a link for registering.
2 thoughts on “FDA Patient-Focused Drug Development Meeting”
I hope there is able to be a large turn out for this. Best wishes ^_^
Me, also Sparrow. They had one earlier this year that seemed to do well.
LikeLiked by 1 person